+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Overactive Bladder Treatment Market - Growth, Trends, COVID-19 Impact, and Forecast (2022 - 2027)

  • PDF Icon


  • 120 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4617264
UP TO OFF until Mar 31st 2024
Over the forecast period, the overactive bladder (OAB) treatment market is expected to register a CAGR of 3.4%. (2022-2027)

COVID-19 is expected to positively impact the overactive bladder treatment market. This is mainly due to the increasing overactive bladder symptoms in the COVID-19 recovered patients. As per the study named Long COVID and COVID-19 Associated Cystitis (CAC) published in Springer Journal in 2021, patients are reported with de novo or worsening overactive bladder symptoms 10-14 weeks after hospitalization with COVID-19. Additionally, the study published by the National Institute of Health (NIH) in 2020 reported that COVID-19 inflammation resulted in urine cytokine elevation, thereby increasing the frequency of urination which leads to overactive bladder disorder among the patients infected with COVID-19. Thus the increase in the COVID-19 infection rate associated with the overactive bladder symptoms increased the demand for the overactive bladder treatment market.

The increasing incidence of diseases, such as Parkinson’s disease, which leads to overactive bladder disorder, and the rising geriatric population, are primary drivers of the global market. In 2020, the United Nations (UN) report showed an estimated 727 million persons aged 65 years or over worldwide. This number is projected to surpass by 2050, reaching over 1.5 billion persons. Urinary incontinence generally increases with aging. The overactive bladder has a major negative impact on the quality of life and health of the aged population. With the increasing burden of overactive bladder, along with other urinary diseases, the growth of the overactive bladder treatment market is likely to be high. Other factors, such as developing innovative intravesical therapies and aggressive marketing by pharmaceutical companies, are also expected to expand the market.

Key Market Trends

Idiopathic Overactive Bladder Treatment Segment is Expected to Hold a Major Share in the Overactive Bladder Treatment Market

Idiopathic overactive bladder treatment is expected to majorly contribute to the revenues over the forecast period, owing to its high prevalence. Due to bladder muscle weakness post-pregnancy and menopause, women are more vulnerable to the condition. According to the Article published in Krager Journal titled 'Mechanism and Priority of Botulinum Neurotoxin A versus Scaral Neuromodulation' for refractory overactive bladder, 2021 overactive bladder is highly prevalent worldwide and found that its overall prevalence was 11.8%. Overactive bladder prevalence in adults over 18 years is 15.6% for men and 17.4% for women in Europe. Also, the same source reported that In Asia, the prevalence of overactive bladder was 5.9% among men and 6.0% among women. This is expected to encourage key market players to invest in this segment. Increasing competition among the market players may decrease the overall cost of treatment during the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to lead the overactive bladder treatment market. This can be credited to its well-established healthcare industry. With reimbursement of overactive bladder treatment, the growing prevalence of the disease with rising age, and the presence of major players, the market is expected to grow during the forecast period. More than 46 million older adults age 65 and older live in the United States; by 2050, that number is expected to grow to almost 90 million, as reported by Rural Health in 2020. Such an increasing number of the vulnerable aging population on the verge of developing overactive bladder disorder is expected to increase the demand for treatment and thereby boost the market's growth. According to the National Association for Incontinence 2020, approximately 25 million adults Americans suffer from some form of urinary incontinence; among them, 75-80% are women. The increasing prevalence of urinary incontinence leading to overactive bladder disorders contributes to the rise in demand for effective treatment. The rising prevalence of bladder over-activity, senior population, healthcare expenditure, and awareness about overactive bladder treatments are the major factors driving the market growth in this region. According to the Center for Medicare and Medicaid Services, United States health care spending grew 9.7% in 2020, reaching USD 4.1 trillion. Therefore, the increasing health care expenditure in this region, which also reflects the increased spending on overactive bladder treatment, is expected to contribute to the market's growth. However, the Asia-Pacific region is expected to register the highest CAGR during the forecast period.

Competitive Landscape

The overactive bladder treatment market is moderately fragmented, with global pharmaceutical companies controlling significant market share. Moreover, the generic space of the market is observing a trend of consolidation and high competition. Major market players include Allergan, Astellas Pharma Inc., Laborie, Endo International PLC, Hisamitsu Pharmaceutical Co. Inc., Johnson & Johnson Services, Inc, Medtronic, Pfizer Inc., and Sanofi, Teva Pharmaceutical Industries Limited, and Macleods Pharmaceuticals Ltd, Urovant Sciences, Uro Medical among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Aging Population and Increasing Prevalence of Diseases Causing Overactive Bladder
4.2.2 Increasing Trend of Drug Development for Overactive Bladder Treatment
4.3 Market Restraints
4.3.1 Side Effects of Current Treatments
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Therapy
5.1.1 Anticholinergics
5.1.2 Mirabegron
5.1.3 Neurostimulation
5.1.4 Intravesical Instillation
5.1.5 Other Therapies
5.2 By Disease Type
5.2.1 Idiopathic Overactive Bladder
5.2.2 Neurogenic Overactive Bladder
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East & Africa GCC South Africa Rest of Middle-East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Allergan
6.1.2 Astellas Pharma Inc.
6.1.3 Laborie
6.1.4 Endo International PLC
6.1.5 Hisamitsu Pharmaceutical Co., Inc.
6.1.6 Johnson & Johnson Services, Inc.
6.1.7 Medtronic
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Teva Pharmaceutical Industries Ltd
6.1.11 Macleods Pharmaceuticals Ltd
6.1.12 Urovant Sciences
6.1.13 Uro Medical


Companies Mentioned

A selection of companies mentioned in this report includes:

  • Allergan
  • Astellas Pharma Inc.
  • Laborie
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Medtronic
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Macleods Pharmaceuticals Ltd
  • Urovant Sciences
  • Uro Medical